Ensign Peak Advisors’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$73.4K Hold
6,737
﹤0.01% 1628
2025
Q4
$87.1K Sell
6,737
-21,350
-76% -$274K ﹤0.01% 1604
2025
Q3
$363K Sell
28,087
-10,200
-27% -$136K ﹤0.01% 1518
2025
Q2
$682K Sell
38,287
-850
-2% -$14.8K ﹤0.01% 1453
2025
Q1
$697K Hold
39,137
﹤0.01% 1435
2024
Q4
$1.17M Hold
39,137
﹤0.01% 1227
2024
Q3
$612K Hold
39,137
﹤0.01% 1552
2024
Q2
$670K Buy
39,137
+2,400
+7% +$42.2K ﹤0.01% 1510
2024
Q1
$574K Sell
36,737
-6,028
-14% -$88.7K ﹤0.01% 1589
2023
Q4
$638K Sell
42,765
-13,630
-24% -$182K ﹤0.01% 1601
2023
Q3
$911K Buy
56,395
+21,625
+62% +$623K ﹤0.01% 1273
2023
Q2
$1.44M Buy
34,770
+5,280
+18% +$328K ﹤0.01% 1006
2023
Q1
$1.77M Buy
29,490
+650
+2% +$51.9K ﹤0.01% 890
2022
Q4
$2.12M Buy
28,840
+4,200
+17% +$316K ﹤0.01% 791
2022
Q3
$1.87M Hold
24,640
﹤0.01% 805
2022
Q2
$1.71M Hold
24,640
﹤0.01% 862
2022
Q1
$2.04M Sell
24,640
-7,030
-22% -$518K ﹤0.01% 882
2021
Q4
$2.38M Buy
31,670
+24,305
+330% +$2.44M ﹤0.01% 897
2021
Q3
$856K Buy
7,365
+1,355
+23% +$205K ﹤0.01% 1485
2021
Q2
$1.33M Buy
+6,010
New +$1.17M ﹤0.01% 1328

Other funds holding NVCR

Ensign Peak Advisors's NVCR Position: Q1 2026 in Review

Ensign Peak Advisors held its NovoCure (NVCR) position steady in Q1 2026 at 6,737 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Ensign Peak Advisors first reported a position in NVCR in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.38M in Q4 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Ensign Peak Advisors held 6,737 shares of NovoCure worth $73.4K as of Q1 2026.
  • Ensign Peak Advisors left its NovoCure share count unchanged in Q1 2026.
  • NovoCure made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1628 holding.
  • Ensign Peak Advisors first reported a position in NovoCure in Q2 2021 and has held it in 20 quarters since.
  • Ensign Peak Advisors's NovoCure position peaked at $2.38M in Q4 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.